Burkard D, et al. - Researchers quantified the beneficial impacts of teriparatide in patients with prior fragility fractures and compared the ability of zoledronic acid and denosumab to maintain the effects. A significant decline in the change in bone mineral density (BMD) was experienced in patients who were elected to discontinue osteoporosis treatment compared to the change on teriparatide, putting them at higher risk for recurrence of fragility fractures. The largest increase in BMD was noted in patients who received denosumab following teriparatide.